RESUMO
Toll-like receptors are important in the activation of innate immunity, and CD40 is a molecule critical for many T and B cell responses. Whereas agonists for either pathway have been used as vaccine adjuvants, we show that a combination of Toll-like receptor (TLR)7 and CD40 agonists synergize to stimulate CD8+ T cell responses 10-20-fold greater than the use of either agonist alone. Antigen-specific CD8+ T cells elicited from combination CD40/TLR7 treatment demonstrated both lytic activities and interferon (IFN)gamma production and an enhanced secondary response to antigenic challenge. Agonists for TLRs 2/6, 3, 4, and 9 also synergized with CD40 stimulation, demonstrating that synergy with the CD40 pathway is a property of TLR-derived stimuli in general. The CD8+ T cell expansion induced by CD40/TLR7 triggering was independent of CD4+ T cells, IFNgamma, and IL-12 but dependent on B7-mediated costimulation and surprisingly on type I IFN. These studies provide the rational basis for the use of TLR and CD40 agonists together as essential adjuvants to optimize vaccines designed to elicit protective or therapeutic immunity.
Assuntos
Adjuvantes Imunológicos/metabolismo , Aminoquinolinas/farmacologia , Linfócitos T CD8-Positivos/imunologia , Imunidade Inata/efeitos dos fármacos , Glicoproteínas de Membrana/agonistas , Receptores de Superfície Celular/agonistas , Transdução de Sinais/imunologia , Vacinas/imunologia , Animais , Anticorpos Monoclonais , Antígenos CD40/metabolismo , Linfócitos T CD8-Positivos/efeitos dos fármacos , Testes Imunológicos de Citotoxicidade , Feminino , Citometria de Fluxo , Imunização , Interferon Tipo I/metabolismo , Interferon gama/imunologia , Interferon gama/metabolismo , Complexo Principal de Histocompatibilidade/imunologia , Camundongos , Camundongos Endogâmicos C57BL , Ovalbumina , Receptor 7 Toll-Like , Receptores Toll-LikeRESUMO
Neuromyelitis optica (NMO) is a severe, debilitating human disease that predominantly features immunopathology in the optic nerves and the spinal cord. An IgG1 autoantibody (NMO-IgG) that binds aquaporin 4 (AQP4) has been identified in the sera of a significant number of NMO patients, as well as in patients with two related neurologic conditions, bilateral optic neuritis (ON), and longitudinal extensive transverse myelitis (LETM), that are generally considered to lie within the NMO spectrum of diseases. NMO-IgG is not the only autoantibody found in NMO patient sera, but the correlation of pathology in central nervous system (CNS) with tissues that normally express high levels of AQP4 suggests NMO-IgG might be pathogenic. If this is the case, it is important to identify and understand the mechanism(s) whereby an immune response is induced against AQP4. This review focuses on open questions about the "events" that need to be understood to determine if AQP4 and NMO-IgG are involved in the pathogenesis of NMO. These questions include: 1) How might AQP4-specific T and B cells be primed by either CNS AQP4 or peripheral pools of AQP4? 2) Do the different AQP4-expressing tissues and perhaps the membrane structural organization of AQP4 influence NMO-IgG binding efficacy and thus pathogenesis? 3) Does prior infection, genetic predisposition, or underlying immune dysregulation contribute to a confluence of events which lead to NMO in select individuals? A small animal model of NMO is essential to demonstrate whether AQP4 is indeed the incipient autoantigen capable of inducing NMO-IgG formation and NMO. If the NMO model is consistent with the human disease, it can be used to examine how changes in AQP4 expression and blood-brain barrier (BBB) integrity, both of which can be regulated by CNS inflammation, contribute to inductive events for anti-AQP4-specific immune response. In this review, we identify reagents and experimental questions that need to be developed and addressed to enhance our understanding of the pathogenesis of NMO. Finally, dysregulation of tolerance associated with autoimmune disease appears to have a role in NMO. Animal models would allow manipulation of hormone levels, B cell growth factors, and other elements known to increase the penetrance of autoimmune disease. Thus an AQP4 animal model would provide a means to manipulate events which are now associated with NMO and thus demonstrate what set of events or multiplicity of events can push the anti-AQP4 response to be pathogenic.
Assuntos
Aquaporina 4/fisiologia , Autoanticorpos/imunologia , Neuromielite Óptica/etiologia , Adulto , Sequência de Aminoácidos , Animais , Aquaporina 4/química , Aquaporina 4/imunologia , Astrócitos/metabolismo , Autoanticorpos/biossíntese , Autoanticorpos/sangue , Barreira Hematoencefálica , Água Corporal/metabolismo , Modelos Animais de Doenças , Células Endoteliais/metabolismo , Epitopos/imunologia , Feminino , Humanos , Imunoglobulina G/biossíntese , Imunoglobulina G/imunologia , Infecções/imunologia , Subpopulações de Linfócitos/imunologia , Masculino , Camundongos , Camundongos Transgênicos , Modelos Moleculares , Modelos Neurológicos , Mimetismo Molecular , Dados de Sequência Molecular , Neuromielite Óptica/genética , Neuromielite Óptica/imunologia , Neuromielite Óptica/fisiopatologia , Conformação Proteica , Medula Espinal/imunologia , Medula Espinal/patologiaRESUMO
Recombinant exotoxin A (rEPA) from Pseudomonas aeruginosa conjugated to Vibrio cholerae O1 serotype-specific polysaccharides (mono-, di- and hexasaccharide) were immunogenic in mice. Monosaccharide conjugates boosted the humoral responses to the hexasaccharide conjugates. Prior exposure to purified Ogawa lipopolysaccharide (LPS) enabled contra-serotype hexasaccharide conjugates to boost the vibriocidal response, but Inaba LPS did not prime for an enhanced vibriocidal response by a contra-serotype conjugate. Prior exposure to the carrier, and priming B cells with the LPS of either serotype, resulted in enhanced vibriocidal titers if the Ogawa hexasaccharides were used, but a diminished response to the Inaba LPS. These studies demonstrate that the 'functional' B cell epitopes on the LPS differ from those of the neoglycoconjugates and that the order of immunization and the serotype of the boosting conjugate can influence the epitope specificity and function of the antisera.
Assuntos
ADP Ribose Transferases/imunologia , Toxinas Bacterianas/imunologia , Vacinas contra Cólera/imunologia , Cólera/imunologia , Exotoxinas/imunologia , Imunoconjugados/imunologia , Oligossacarídeos/imunologia , Vibrio cholerae O1/imunologia , Fatores de Virulência/imunologia , ADP Ribose Transferases/química , ADP Ribose Transferases/farmacologia , Animais , Toxinas Bacterianas/química , Toxinas Bacterianas/farmacologia , Configuração de Carboidratos , Sequência de Carboidratos , Cólera/microbiologia , Cólera/prevenção & controle , Cólera/virologia , Vacinas contra Cólera/química , Vacinas contra Cólera/farmacologia , Exotoxinas/química , Exotoxinas/farmacologia , Feminino , Imunoconjugados/química , Imunoconjugados/farmacologia , Imunoglobulina M/imunologia , Lipopolissacarídeos/imunologia , Lipopolissacarídeos/farmacologia , Camundongos , Camundongos Endogâmicos BALB C , Dados de Sequência Molecular , Oligossacarídeos/química , Vibrio cholerae O1/química , Fatores de Virulência/química , Fatores de Virulência/farmacologia , Exotoxina A de Pseudomonas aeruginosaRESUMO
Ogawa hexasaccharide neoglycoconjugates induce protective antibodies in mice. Similar Ogawa conjugates but with a longer linker that connects the carrier to shorter saccharides are immunogenic, but generally ineffective at inducing vibriocidal or protective antibodies. The efficacy of Ogawa hexasaccharide neoglycoconjugates of different linker lengths were tested. The majority of mice given immunizations separated by a 14-day gap did not produce vibriocidal or protective antibodies. Mice immunized 28 days apart with immunogens containing the shortest or medium length linker, but not the longest, produced vibriocidal and protective antibodies. A nonprotective, priming dose of purified Ogawa LPS followed 5 days later with a booster of the Ogawa neoglycoconjugates (di-, tetra-, or hexasaccharide) resulted in vibriocidal antibodies at day 10.
Assuntos
Vacinas contra Cólera/imunologia , Lipopolissacarídeos/imunologia , Antígenos O/imunologia , Vibrio cholerae O1/imunologia , Animais , Anticorpos Antibacterianos/biossíntese , Anticorpos Antibacterianos/imunologia , Linfócitos B/imunologia , Sequência de Carboidratos , Vacinas contra Cólera/química , Feminino , Imunoglobulina M/biossíntese , Imunoglobulina M/imunologia , Memória Imunológica , Lipopolissacarídeos/química , Camundongos , Camundongos Endogâmicos BALB C , Dados de Sequência Molecular , Antígenos O/química , Gravidez , Soroalbumina Bovina/química , Soroalbumina Bovina/imunologia , Relação Estrutura-AtividadeRESUMO
Toll-like receptors (TLRs) recognize pathogen-associated molecular patterns, which are non-self macromolecular components of pathogens that allow the innate-immune system to recognize infection. TLRs are expressed on macrophages and dendritic cells (DC). TLR stimulation or CD40 agonists can induce inflammatory cytokine secretion from macrophages and DC, and promote DC maturation. The regulation of TLR expression by inflammation has begun to be explored. Our studies have focused on the regulation of TLR4 surface expression on DC. TLR4, along with the adaptor molecule MD2, is involved in the recognition of lipopolysaccharide (LPS). CD40 stimulation via cross-linked anti-CD40 monoclonal antibody (mAb) up-regulates TLR4-MD2 surface expression on a DC cell line (DC2.4) and on ex vivo-cultured splenic DC. LPS treatment down-regulated surface TLR4-MD2 on DC2.4 cells, but if combined with anti-CD40 mAb, increased TLR4-MD2 expression was observed. The increased TLR4-MD2 surface expression by any treatment did not correlate with TLR4 mRNA levels. The functional consequence of increased TLR4-MD2 expression following LPS and anti-CD40 treatment was examined. Although CD40 prestimulation did slightly enhance interleukin-12p70 secretion after LPS restimulation, simultaneous anti-CD40 mAb and LPS treatment, which up-regulates TLR4-MD2 complex, does not restore DC responsiveness to subsequent LPS.
Assuntos
Antígenos Ly/metabolismo , Antígenos CD40/metabolismo , Células Dendríticas/metabolismo , Glicoproteínas de Membrana/metabolismo , Receptores de Superfície Celular/metabolismo , Adjuvantes Imunológicos , Animais , Antígenos Ly/genética , Ensaio de Imunoadsorção Enzimática , Feminino , Genes RAG-1/fisiologia , Interleucina-12/metabolismo , Lipopolissacarídeos/metabolismo , Antígeno 96 de Linfócito , Glicoproteínas de Membrana/genética , Camundongos , Camundongos Endogâmicos C57BL , Camundongos Knockout , RNA Mensageiro/efeitos dos fármacos , RNA Mensageiro/metabolismo , Receptores de Superfície Celular/genética , Reação em Cadeia da Polimerase Via Transcriptase Reversa , Baço/imunologia , Baço/metabolismo , Receptor 4 Toll-Like , Receptores Toll-Like , Regulação para CimaRESUMO
A synthetic hexasaccharide, identical to the terminal hexasaccharide of Ogawa LPS, coupled to bovine serum albumin induced protective antibodies in mice. To determine if there was a minimum saccharide length required for immunogenicity and efficacy, shorter (mono- to pentasaccharide) neoglycoconjugates (CHO-BSA) were tested in mice. The Ogawa CHO-BSA was inoculated at either a constant mass but differing moles, or equal moles but differing masses. Humoral responses were essentially the same when mice received 9 microg of the carbohydrate (0.007 mM with the pentasaccharide) in each of the neoglycoconjugates prepared from mono- through the pentasaccharide, or the same molar amount (0.007 mM), proportionally less by weight when going from the penta- to the monosaccharide. These data show that, within this dose range, the responses occurred virtually independently of the amount of immunogen. Humoral antibodies induced by these immunogens were generally not vibriocidal. Selected antisera induced by CHO-BSA immunogens were protective, but the ELISA titers of the sera were not predictive of the protective capacity. Purified, Ogawa LPS induced anti-Ogawa LPS IgM antibody titers similar to those induced by the Ogawa CHO-BSA conjugates. The anti-whole LPS sera were strongly vibriocidal, as were the previously reported sera induced by hexasaccharide conjugates. This suggests either that the shorter oligosaccharides lack a conformational epitope provided by the hexasaccharide or that the LPS has additional B cell epitopes or selects different B cells in the primary response.
Assuntos
Antígenos O/imunologia , Fragmentos de Peptídeos/imunologia , Vibrio cholerae O1/classificação , Vibrio cholerae O1/imunologia , Animais , Anticorpos Antibacterianos/biossíntese , Anticorpos Antibacterianos/sangue , Relação Dose-Resposta Imunológica , Feminino , Glicoconjugados/imunologia , Imunoglobulina M/biossíntese , Imunoglobulina M/sangue , Lipopolissacarídeos/imunologia , Camundongos , Camundongos Endogâmicos BALB C , Antígenos O/química , Fragmentos de Peptídeos/química , SorotipagemRESUMO
Cholera, an enteric disease that can reach pandemic proportions, remains a world-wide problem that is positioned to increase in incidence as changes in global climate or armed conflict spawn the conditions that enhance transmission to humans and, thus, precipitate epidemic cholera. An effective subunit cholera vaccine that can provide protective immunity with one parenteral immunization would be a major advantage over the existing oral vaccines that can require two doses for optimal protection. The existing vaccines are clearly effective in some settings, but are less so in others, especially with respect to specific groups such as young (2-5 years) children. In our efforts to develop a cholera subunit vaccine, we focused on two Vibrio cholerae antigens, LPS (lipopolysaccharide) and TCP (toxin co-regulated pilus), that are known to induce protective antibodies in animal models and, in the case of anti-LPS antibodies, to be associated with clinical protection of V. cholerae exposed or vaccinated individuals. This review discusses the current cholera vaccines and compares the advantages of a cholera subunit vaccine to that of the whole cell vaccines. We discuss the possible subunit antigens and prospective targeted use of a subunit cholera vaccine.
Assuntos
Vacinas contra Cólera/química , Cólera/prevenção & controle , Animais , Cólera/transmissão , Vacinas contra Cólera/uso terapêutico , Humanos , Tecnologia Farmacêutica/tendências , Vacinas Atenuadas/química , Vacinas Atenuadas/uso terapêutico , Vacinas de Produtos Inativados/química , Vacinas de Produtos Inativados/uso terapêutico , Vacinas de Subunidades Antigênicas/química , Vacinas de Subunidades Antigênicas/uso terapêuticoRESUMO
The emergence of Vibrio cholerae (Vc) lipopolysaccharide (LPS) as a lead protective antigen for a cholera subunit vaccine has increased the interest in what type of B cell is best suited to generate anti-Vc LPS antibodies. A related question is what form of LPS is the most immunogenic. C57Bl/6 (B6) neonatal mice (10 days old) whose marginal zone (MZ) B cell compartment is still maturing and two lines of knockout mice that either lack the signaling mechanism required for the maturation of MZ B cells or that lack a receptor required for MZ B cell retention in the MZ were used to determine the role of MZ B cells in anti-Vc LPS antibody responses. Data support the conclusion that MZ B cells play a significant role in the anti-Vc LPS antibody response. Serum and vibriocidal antibody titers also depend on whether the Vc LPS is purified or bacterial cell-associated.
Assuntos
Anticorpos Antibacterianos/sangue , Linfócitos B/imunologia , Lipopolissacarídeos/imunologia , Vibrio cholerae/imunologia , Animais , Animais Recém-Nascidos , Formação de Anticorpos , Atividade Bactericida do Sangue , Camundongos Endogâmicos C57BL , Camundongos KnockoutRESUMO
Worldwide, in endemic areas of cholera, the group most burdened with cholera is children. This is especially vexing as young children (2-5 years of age) do not respond as well, or for as long as adults do, to the current killed oral cholera vaccines (OCV). Conjugate vaccines based on the hapten-carrier paradigm have been developed for several bacterial pathogens that cause widespread and severe diseases in young children. We and others have studied different formulations of Vibrio cholerae (Vc) O1 lipopolysaccharide (LPS, a T-independent antigen) conjugates. Detoxified LPS is a central component of a LPS-based conjugate vaccine. pmLPS, which is detoxified by acid treatment, is a superior immunogen compared with hydrazine-detoxified LPS (DetAcLPS) that has altered lipid A acyl chains. The other feature of pmLPS is the ability to link carrier proteins to a core region of sugar. pmLPS readily induced vibriocidal antibodies following one intraperitoneal dose in a MPL-type adjuvant One dose of the pmLPS conjugate was suggestive of being protective; a booster resulted in protective antibodies for infant mice challenged with virulent cholera.
Assuntos
Anticorpos Antibacterianos/sangue , Vacinas contra Cólera/imunologia , Cólera/imunologia , Cólera/prevenção & controle , Lipopolissacarídeos/imunologia , Vacinas Conjugadas/imunologia , Vibrio cholerae/patogenicidade , Ácido Acético/farmacologia , Animais , Anticorpos Antibacterianos/imunologia , Cólera/microbiologia , Vacinas contra Cólera/química , Feminino , Humanos , Hidrazinas/farmacologia , Lipopolissacarídeos/química , Camundongos , Vacinas Conjugadas/química , Vibrio cholerae/efeitos dos fármacos , Vibrio cholerae/imunologiaRESUMO
The number of cholera vaccine doses required for immunity is a constraint during epidemic cholera. Protective immunity following one dose of multiple Vibrio cholerae (Vc) colonization factors (Inaba LPS El Tor, TcpA, TcpF, and CBP-A) has not been directly tested even though individual Vc colonization factors are the protective antigens. Inaba LPS consistently induced vibriocidal and protective antibodies at low doses. A LPS booster, regardless of dose, induced highly protective secondary sera. Vc protein immunogens emulsified in adjuvant were variably immunogenic. CBP-A was proficient at inducing high IgG serum titers compared with TcpA or TcpF. After one immunization, TcpA or TcpF antisera protected only when the toxin co-regulated pilus operon of the challenge Vc was induced by AKI culture conditions. CBP-A was not consistently able to induce protection independent of the challenge Vc culture conditions. These results reveal the need to understand how best to leverage the 'right' Vc immunogens to obtain durable immunity after one dose of a cholera subunit vaccine. The dominance of the protective anti-LPS antibody response over other Vc antigen antibody response needs to be controlled to find other protective antigens that can add to anti-LPS antibody-based immunity.
Assuntos
Vacinas contra Cólera/administração & dosagem , Vacinas contra Cólera/imunologia , Cólera/imunologia , Cólera/prevenção & controle , Vacinação/métodos , Vibrio cholerae/imunologia , Adjuvantes Imunológicos/administração & dosagem , Animais , Anticorpos Antibacterianos/sangue , Antígenos de Bactérias/administração & dosagem , Antígenos de Bactérias/imunologia , Feminino , Imunoglobulina G/sangue , Camundongos , Camundongos Endogâmicos BALB CRESUMO
Antibodies and immune effectors (IE) are crucial for protecting humans from Gram-negative bacteria. Antibodies can bind outer membrane or cell surface (e.g. flagella) structures, thereby preventing adhesion, disrupting specific virulence functions, or targeting bacteria for phagocytosis. IE (antimicrobial peptides, cytokines and hormones) impinge on bacterial infections and regulate immune responses. A developing paradigm is that bacteria 'recognize' antibodies and IE, which alert them to challenging environments, promoting resistance phenotypes and increased virulence. A broader understanding of the interactions between bacteria and antibodies and IE will help define their relative contributions to pathogenesis, and perhaps indicate how we could use antibodies and IE to shape bacterial phenotypes that are easier for the immune system to control.
Assuntos
Anticorpos Antibacterianos/imunologia , Peptídeos Catiônicos Antimicrobianos/metabolismo , Citocinas/metabolismo , Bactérias Gram-Negativas/imunologia , Bactérias Gram-Negativas/patogenicidade , Infecções por Bactérias Gram-Negativas/microbiologia , Hormônios/metabolismo , Adaptação Fisiológica , Imunidade Adaptativa , Cápsulas Bacterianas/imunologia , Proteínas da Membrana Bacteriana Externa/imunologia , Regulação Bacteriana da Expressão Gênica , Bactérias Gram-Negativas/genética , Bactérias Gram-Negativas/metabolismo , Infecções por Bactérias Gram-Negativas/imunologia , Humanos , Linfócitos/imunologia , Fenótipo , Virulência , Fatores de Virulência/metabolismoRESUMO
Vibrio cholerae causes cholera, an enteric disease of humans that is a worldwide problem. The O1 serogroup of Vibrio cholerae contains two predominant serotypes (Inaba and Ogawa) of LPS, a proven protective antigen for humans and experimental animals. We generated B-cell hybridomas from mice immunized with either: (i) two doses of purified Inaba LPS; (ii) two doses of an Inaba hexasaccharide conjugate (terminal six perosamine bound to a protein carrier), (iii) four doses of purified Inaba LPS; or (iv) a low dose of purified Inaba LPS followed by a booster with the Inaba conjugate. We showed previously that the first and third immunization protocols induce vibriocidal antibodies, as does the fourth; the second protocol induces antibodies that bind Inaba and Ogawa LPS but are not vibriocidal. Anti-LPS mAbs derived from hybridomas resulting from each immunization protocol were characterized for binding to Inaba and Ogawa LPS, their vibriocidal or protective capacity, and the variable heavy chain family they expressed. LPS immunogens selected different LPS-specific B cells expressing six different Vh chain families. Protective and non-protective mAbs could express variable regions from the same family. One mAb was specific for Inaba LPS, the other mAbs were cross-reactive with both LPS serotypes. Sequence comparison suggests that the pairing of a specific light chain, somatic mutation, or the specific VDJ recombination can modulate the protective capacity of mAbs that express a common variable heavy chain family member.
Assuntos
Anticorpos Antibacterianos/genética , Cólera/imunologia , Cadeias Pesadas de Imunoglobulinas/genética , Lipopolissacarídeos/imunologia , Vibrio cholerae O1/imunologia , Sequência de Aminoácidos , Animais , Anticorpos Antibacterianos/química , Anticorpos Antibacterianos/imunologia , Cólera/microbiologia , Feminino , Humanos , Hibridomas/imunologia , Cadeias Pesadas de Imunoglobulinas/química , Cadeias Pesadas de Imunoglobulinas/imunologia , Camundongos , Camundongos Endogâmicos BALB C , Dados de Sequência Molecular , Alinhamento de SequênciaRESUMO
PROBLEM: Cholera is the paradigm for waterborne bacterial diseases. For over a 100 years, scientists have tried to develop a universally effective vaccine for cholera. We are hampered in our efforts because we do not know the details of the basic immune response to Vibrio cholerae antigens. What are the most proactive antigens? What special needs for immunization are engendered by previous exposure to cholera or the age of the individual? How long does immunity last, and is this immunity a classic immunologic memory or re-exposure and continual boosting? METHOD OF STUDY: Immunization with synthetic derivatives of the carbohydrate moieties of V. cholerae lipopolysaccharide (LPS) coupled to different carrier proteins (neoglycoconjugates, NGC) has allowed dissection of the response to the disaccharide array of perosamine that represent either the Inaba or the Ogawa serotype. Studying serum anti-LPS endpoint titers and the serum vibriocidal response to NGC provides insight into the importance of LPS serotype-specific B-cell epitopes and how antibody response are influenced by the form of the LPS immunogen. RESULTS: We found that murine serum antibody responses to V. cholerae LPS are dynamic. The magnitude of serum anti-LPS antibody titers and the capacity to induced vibriocidal antibodies (immunoglobulin M) are influenced by the initial immunizing serotype of LPS, the structure of the LPS immunogen (native LPS versus NGC), and the order of serotype immunization in a prime boost immunization strategy. The dynamic of the immune response to LPS immunogens is typified by the fact that the host species can affect the immunization response. We found mice do not make vibriocidal antibody to Inaba NGC but rabbits do. This is in contrast to the Ogawa NGC that induced vibriocidal antibody in mice. CONCLUSION: The results suggest that the host's B-cell repertoire can influence the immunization efficacy; therefore, the development of the new generation of NGC V. cholerae vaccines should focus on human volunteers and their ability to mount protective responses.
Assuntos
Linfócitos B/imunologia , Epitopos de Linfócito B/imunologia , Lipopolissacarídeos/imunologia , Animais , Vacinas Bacterianas/imunologia , Lipopolissacarídeos/química , Camundongos , Estrutura Molecular , Vibrio cholerae/imunologiaRESUMO
Cholera, a diarrheal disease, is known for explosive epidemics that can quickly kill thousands. Endemic cholera is a seasonal torment that also has a significant mortality. Not all nations with extensive rural communities can achieve the required infrastructure or behavioral changes to prevent epidemic or endemic cholera. For some communities, a single-dose cholera vaccine that protects those at risk is the most efficacious means to reduce morbidity and mortality. It is clear that our understanding of what a protective cholera immune response is has not progressed at the rate our understanding of the pathogenesis and molecular biology of cholera infection has. This review addresses V. cholerae lipopolysaccharide (LPS)-based immunogens because LPS is the only immunogen proven to induce protective antibody in humans. We discuss the role of anti-LPS antibodies in protection from cholera, the importance and the potential role of B cell subsets in protection that is based on their anatomical location and the intrinsic antigen-receptor specificity of various subsets is introduced.
Assuntos
Linfócitos B/imunologia , Vacinas contra Cólera/imunologia , Cólera/imunologia , Lipopolissacarídeos/imunologia , Vibrio cholerae/imunologia , Anticorpos Antibacterianos/biossíntese , Linfócitos B/efeitos dos fármacos , Vacinas contra Cólera/administração & dosagem , HumanosRESUMO
Studies have demonstrated that receptor-mediated signaling, receptor/antigen complex trafficking, and major histocompatibility complex class II compartments (MIIC) are critically related to antigen presentation to CD4+ T cells. In this study, we investigated the role of protein kinase C (PKC) in FcalphaR/gammagamma (CD89, human IgA receptor)-mediated internalization of immune complexes and subsequent antigen presentation. The classical and novel PKC inhibitor, Calphostin C, inhibits FcalphaR-mediated antigen presentation and interaction of MIIC and cargo vesicle (receptor and antigen). PKC-alpha, PKC-delta, and PKC-epsilon were recruited to lipid rafts following FcalphaR crosslinking, the extent of which was determined by the phenotype of the gamma chain. Mutant gamma chain with an FcgammaRIIA ITAM (immunoreceptor tyrosine-based activation motif) insert was less able to recruit PKC and trigger antigen presentation. Both PKC isoform-specific peptide inhibitors and short interfering RNA (siRNA) showed that PKC-alpha and PKC-delta, but not PKC-epsilon, were required for association of cargo vesicle and MIIC and for FcalphaR-mediated and soluble antigen presentation. Inhibition of PKC (classical and novel) did not alter major histocompatibility class II biosynthesis, assembly, transport, or plasma membrane stability. PKC's role in facilitating interaction of cargo vesicle and MIIC is likely due to regulation of vesicle biology required for fusion of cargo vesicles to MIIC.
Assuntos
Apresentação de Antígeno , Antígenos CD/metabolismo , Genes MHC da Classe II , Proteína Quinase C/metabolismo , Receptores Fc/metabolismo , Animais , Linfócitos B/citologia , Linfócitos B/metabolismo , Linhagem Celular , Endocitose/fisiologia , Ativação Enzimática , Humanos , Isoenzimas/genética , Isoenzimas/metabolismo , Proteínas de Membrana Lisossomal , Microdomínios da Membrana/metabolismo , Naftalenos/metabolismo , Proteína Quinase C/antagonistas & inibidores , Proteína Quinase C/genética , Proteína Quinase C-alfa , Proteína Quinase C-delta , Proteína Quinase C-épsilon , Transporte Proteico/fisiologia , RNA Interferente Pequeno/genética , RNA Interferente Pequeno/metabolismo , Transdução de Sinais/fisiologia , Vesículas Transportadoras/metabolismoRESUMO
Vibrio cholerae is a gram-negative bacterium that has been associated with cholera pandemics since the early 1800s. Whole-cell, killed, and live-attenuated oral cholera vaccines are in use. We and others have focused on the development of a subunit cholera vaccine that features standardized epitopes from various V. cholerae macromolecules that are known to induce protective antibody responses. TcpA protein is assembled into toxin-coregulated pilus (TCP), a type IVb pilus required for V. cholerae colonization, and thus is a strong candidate for a cholera subunit vaccine. Polypeptides (24 to 26 amino acids) in TcpA that can induce protective antibody responses have been reported, but further characterization of their amino acid targets relative to tertiary or quaternary TCP structures has not been done. We report a refinement of the TcpA sequences that can induce protective antibody. One sequence, TcpA 15 (residues 170 to 183), induces antibodies that bind linear TcpA in a Western blot as well as weakly bind soluble TcpA in solution. These antibodies bind assembled pili at high density and provide 80 to 100% protection in the infant mouse protection assay. This is in sharp contrast to other anti-TcpA peptide sera (TcpA 11, TcpA 13, and TcpA 17) that bind very strongly in Western blot and solution assays yet do not provide protection or effectively bind TCP, as evidenced by immunoelectron microscopy. The sequences of TcpA 15 that induce protective antibody were localized on a model of assembled TCP. These sequences are centered on a site that is predicted to be important for TCP structure.
Assuntos
Anticorpos Antibacterianos/imunologia , Proteínas de Fímbrias/química , Proteínas de Fímbrias/imunologia , Fímbrias Bacterianas/química , Fímbrias Bacterianas/imunologia , Vibrio cholerae/imunologia , Sequência de Aminoácidos , Animais , Animais Recém-Nascidos , Especificidade de Anticorpos , Cólera/imunologia , Cólera/prevenção & controle , Vacinas contra Cólera/química , Vacinas contra Cólera/imunologia , Ensaio de Imunoadsorção Enzimática , Feminino , Proteínas de Fímbrias/genética , Soros Imunes/imunologia , Camundongos , Modelos Moleculares , Conformação Proteica , Coelhos , Proteínas Recombinantes/química , Proteínas Recombinantes/genética , Proteínas Recombinantes/imunologia , Solubilidade , Taxa de Sobrevida , Vibrio cholerae/ultraestrutura , VirulênciaRESUMO
Development of Vibrio cholerae lipopolysaccharide (LPS) as a cholera vaccine immunogen is justified by the correlation of vibriocidal anti-LPS response with immunity. Two V. cholerae O1 LPS serotypes, Inaba and Ogawa, are associated with endemic and pandemic cholera. Both serotypes induce protective antibody following infection or vaccination. Structurally, the LPSs that define the serotypes are identical except for the terminal perosamine moiety, which has a methoxyl group at position 2 in Ogawa but a hydroxyl group in Inaba. The terminal sugar of the Ogawa LPS is a protective B-cell epitope. We chemically synthesized the terminal hexasaccharides of V. cholerae serotype Ogawa, which comprises in part the O-specific polysaccharide component of the native LPS, and coupled the oligosaccharide at different molar ratios to bovine serum albumin (BSA). Our initial studies with Ogawa immunogens showed that the conjugates induced protective antibody. We hypothesized that antibodies specific for the terminal sugar of Inaba LPS would also be protective. Neoglycoconjugates were prepared from synthetic Inaba oligosaccharides (disaccharide, tetrasaccharide, and hexasaccharide) and BSA at different levels of substitution. BALB/c mice responded to the Inaba carbohydrate (CHO)-BSA conjugates with levels of serum antibodies of comparable magnitude to those of mice immunized with Ogawa CHO-BSA conjugates, but the Inaba-specific antibodies (immunoglobulin M [IgM] and IgG1) were neither vibriocidal nor protective in the infant mouse cholera model. We hypothesize that the anti-Inaba antibodies induced by the Inaba CHO-BSA conjugates have enough affinity to be screened via enzyme-linked immunosorbent assay but not enough to be protective in vivo.
Assuntos
Anticorpos/imunologia , Antígenos O/imunologia , Vibrio cholerae O1/imunologia , Animais , Feminino , Camundongos , Antígenos O/metabolismo , Soroalbumina Bovina/metabolismoRESUMO
The human IgA Fc receptor (FcalphaR, CD89) triggers several important physiological functions, including phagocytosis, NADPH oxidase activation and antigen presentation. Efforts are underway to delineate FcalphaR signal-transduction pathways that control these functions. In a previous study, we demonstrated that cross-linking of FcalphaR increased its partitioning into membrane glycolipid rafts and was accompanied by gamma-chain-dependent recruitment and phosphorylation of the tyrosine kinases Lck/Yes-related novel protein tyrosine kinase (Lyn) and Bruton's tyrosine kinase (Btk). Here we have performed a more extensive characterization of signalling effectors recruited to rafts on FcalphaR cross-linking. We demonstrate that in addition to tyrosine kinases Lyn and Btk, FcalphaR cross-linking also recruits B-lymphocyte kinase (Blk) and spleen tyrosine kinase (Syk) to rafts. We show recruitment of phosphoinositide kinases, including 3-phosphoinositide 3-kinase and phospholipase Cgamma2, and serine/threonine kinases such as protein kinase C (PKC) alpha, PKCepsilon, and protein kinase B (PKB) alpha. This suggests that lipid rafts serve as sites for FcalphaR-triggered recruitment of multiple classes of signalling effectors. We further demonstrate that tyrosine kinases and PKCalpha have a sustained association with rafts, whereas phosphoinositide 3-kinase and its downstream effectors have a transient association with rafts. This is consistent with temporally regulated divergence of FcalphaR signalling pathways in rafts. Furthermore, we suggest the spatial separation of signalling effectors by transport of phosphoinositide 3-kinase, phosphoinositide-dependent kinase 1, PKBalpha and PKCepsilon to endocytic compartments containing internalized FcalphaR.
Assuntos
1-Fosfatidilinositol 4-Quinase/metabolismo , Reagentes de Ligações Cruzadas/metabolismo , Glicolipídeos/metabolismo , Proteínas Serina-Treonina Quinases/metabolismo , Proteínas Tirosina Quinases/metabolismo , Receptores Fc/metabolismo , 1-Fosfatidilinositol 4-Quinase/antagonistas & inibidores , Eletroforese em Gel de Poliacrilamida , Inibidores Enzimáticos/farmacologia , Fosforilação , Proteínas Serina-Treonina Quinases/antagonistas & inibidores , Proteínas Tirosina Quinases/antagonistas & inibidores , Transdução de SinaisRESUMO
Dendritic cells (DCs) can be matured by CD40 stimulation to upregulate their MHC class II/peptide complexes and costimulatory molecule surface expression to become adept at presenting antigen to and activating naive T lymphocytes. The use of anti-CD40 antibodies as adjuvants for DC-based therapy has been advanced. Little is known as to how DC biology in response to CD40 ligation differs between in vitro versus in vivo ligation. Therefore, the authors analyzed the expression kinetics of MHC class II (I-Ak)/HEL peptide "complex," total MHC class II, CD80, and CD86 on in vitro or in vivo CD40-stimulated DCs over a period of 5 days. MHC class II, "complex," and costimulatory molecule expression was elevated at 1 day in vitro and stayed high for the culture period, whereas in vivo expression of the cohort of molecules peaked earlier and then declined. When purified DCs were co-cultured in vitro with antigen-specific T cell hybridomas, the DCs had lower expression of total MHC class II and "complex," but did not reduce their CD80 and CD86 expression. The lower expression was dependent on cognate interaction as a non-antigen-specific T cell hybridoma was without effect. Blocking antigen-specific MHC class II/peptide-T cell receptor (TcR) complex interaction with antibody inhibited the reduction of MHC class II expression on CD40-stimulated DCs in vitro. Overall, their studies suggest distinct response of DCs to typical conditions that feature anti-CD40 monoclonal antibody (mAb)-activated DCs in vitro or in vivo.
Assuntos
Antígenos CD40/imunologia , Células Dendríticas/imunologia , Genes MHC da Classe II/genética , Animais , Anticorpos Monoclonais/farmacologia , Apresentação de Antígeno , Células Cultivadas , Citometria de Fluxo , Expressão Gênica , Técnicas In Vitro , Ativação Linfocitária , Camundongos , Camundongos Endogâmicos C3H , Modelos Animais , Probabilidade , Regulação para CimaRESUMO
Synthetic antigens that mimic the terminal hexasaccharide epitope of the O-specific polysaccharide of Vibrio cholerae O1, serotype Ogawa, were conjugated to bovine serum albumin (BSA). Conjugates with carbohydrate-to-carrier molar ratios of 15.5:1, 9.2:1, and 4.6:1 were tested for immunogenicity and efficacy in mice. The role of preimmunity to BSA and the use of adjuvant in the generation of the serologic response to the O-specific polysaccharide and protection against virulent V. cholerae was examined. Preimmunity to BSA did not affect the anti-Ogawa titers but seemed to enhance the protective capacity of antiserum. All 3 conjugates were immunogenic, but adjuvant was effective at inducing higher and earlier antibody responses. In tertiary serum samples, a correlation was found between vibriocidal activity and protection. The protective capacity of antiserum was evident in serum from mice immunized with all conjugates, but it was highest in the groups that received the conjugate with the lowest level of substitution. Further studies are required to increase understanding of the reason for differential protection.